Scientists have developed the world’s first drug, muvalaplin, to treat high levels of lipoprotein(a), a type of “bad cholesterol” linked to increased risk of heart attacks and strokes. The drug successfully lowered lipoprotein(a) levels by up to 65% in a phase I clinical trial, proving to be safe with minimal side effects. People of African and South Asian descent are most at risk for high levels of lipoprotein(a). The drug is considered a game-changer in treating this previously untreatable form of cholesterol. Phase II trials are underway to determine its effectiveness in reducing heart attacks caused by elevated lipoprotein(a) levels.
Source link